Market Spotlight: Benign Prostatic Hyperplasia (BPH)
Market Spotlight: Benign Prostatic Hyperplasia (BPH)
$1,318.00
This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 319.8 million prevalent cases of benign prostatic hyperplasia (BPH) among males aged 40 years and older worldwide, and forecasts that number to increase to 389.8 million prevalent cases by 2030.
- Asia is estimated to have had the largest number of prevalent cases in 2021, and Oceania is estimated to have had the smallest number (197.9 million and 2.1 million cases, respectively).
- Approved drugs in the BPH space target phosphodiesterase 5, steroid 5a-reductase, alpha 1 adrenergic receptor, and muscarinic acetylcholine receptor. All marketed drugs for BPH are administered via the oral route.
- The only industry-sponsored drug in active clinical development for BPH is in Phase III. The only therapy in active clinical development for BPH targets apoptosis and mitochondria. It is being tested in an intratumoral formulation.
- The overall likelihood of approval of a Phase I urology asset is 8.3%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 9.7 years from Phase I to approval in the overall urology space.
- There are equal proportions of clinical trials for BPH across all phases of development. The US has a substantial lead in the number of BPH clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the BPH space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for BPH, with 44 trials.
- GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for BPH, followed by Astellas and Sanofi.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Watchful waiting
8 Pharmacological treatment
8 Surgical treatment
10 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
21 RECENT EVENTS AND ANALYST OPINION
21 Fexapotide for BPH (May 20, 2022)
23 KEY REGULATORY EVENTS
23 FDA Nixes Nymox NDA For Lack Of Long-Term Safety Data
23 Nymox Fexapotide Odyssey Reaches FDA
24 PROBABILITY OF SUCCESS
25 LICENSING AND ASSET ACQUISITION DEALS
25 Torrent Acquires Chronic Brands From Dr Reddy’s, Folds Up US Liquids Business
26 REVENUE OPPORTUNITY
28 CLINICAL TRIAL LANDSCAPE
29 Sponsors by status
30 Sponsors by phase
32 BIBLIOGRAPHY
33 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of BPH, 2021–30
17 Figure 2: Overview of pipeline drugs for BPH in the US
17 Figure 3: Pipeline drugs for BPH, by company
17 Figure 4: Pipeline drugs for BPH, by drug type
18 Figure 5: Pipeline drugs for BPH, by classification
24 Figure 6: Probability of success in the urology pipeline
28 Figure 7: Clinical trials in BPH
28 Figure 8: Top 10 drugs for clinical trials in BPH
29 Figure 9: Top 10 companies for clinical trials in BPH
29 Figure 10: Trial locations in BPH
30 Figure 11: BPH trials status
31 Figure 12: BPH trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of BPH, 2021–30
13 Table 2: Prevalence proportions of BPH, by age
15 Table 3: Marketed drugs for BPH
19 Table 4: Pipeline drugs for BPH in the US
21 Table 5: Fexapotide for BPH (May 20, 2022)
26 Table 6: Historical global sales, by drug ($m), 2017–21
27 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Sarcoma 
Sign up to the